Loading
Life sciences · Journal article
Cell and Gene Therapy Insights · September 24, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
“As a physician, my goal is to develop a therapy that all intended patients, and healthcare systems, can afford and deliver.”Abi Pinchbeck, Commissioning Editor, Cell & Gene Therapy Insights, speaks with Dr Frank Borriello, CEO, Alloplex Biotherapeutics, about a non-engineered, autologous approach to cancer immunotherapy. They discuss the ENLYST platform and multi-pathway immune cell activation, the SUPLEXA manufacturing process, comparability across variable autologous starting material, durability, and persistence, and the potential of decentralized manufacturing to improve patient access. They also explore how in vivo and ex vivo CAR-T fit into the evolving cell therapy landscape.